Welcome to our dedicated page for Edap Tms news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on Edap Tms stock.
EDAP TMS SA (NASDAQ: EDAP) delivers innovative therapeutic ultrasound solutions for urological care through its HIFU and lithotripsy technologies. This news hub provides investors and medical professionals with essential updates on the company's advancements in robotic medical devices, regulatory milestones, and global market strategies.
Access real-time announcements including clinical trial results, product approvals, financial disclosures, and strategic partnerships. Our curated collection features press releases about EDAP's three operational divisions: HIFU tumor ablation systems, ESWL stone treatment devices, and distribution of complementary medical technologies.
Stay informed about developments in minimally-invasive treatment solutions that demonstrate EDAP's commitment to advancing urological care. The resource is regularly updated with material events affecting the company's position in the competitive medical devices sector.
Bookmark this page for streamlined access to verified information about EDAP's technological innovations, international expansion efforts, and research collaborations with leading medical institutions.
EDAP TMS SA (Nasdaq: EDAP) announced its participation in two significant urology congresses: the EAU Congress in Amsterdam from July 1-4, 2022, and the SRS Congress in Orlando from June 30 to July 3, 2022. At these events, EDAP will showcase its Focal One® Robotic Focal HIFU technology, emphasizing its role in prostate cancer treatment. Key presentations will include a randomized trial comparing ExactVu micro-ultrasound with MRI and discussions on the growing adoption of Focal One as a minimally invasive therapy. This involvement is expected to enhance EDAP's visibility and customer engagement in the urology space.
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, announced that Prof. Gil Dubernard will present at the 6th European Endometriosis Congress in Bordeaux, France, on June 17. The presentation will focus on the potential of High Intensity Focused Ultrasound (HIFU) as a treatment for symptomatic rectal endometriosis. CEO Marc Oczachowski emphasized the importance of this research, which suggests that HIFU may provide a less invasive option for patients suffering from endometriosis.
EDAP TMS SA (Nasdaq: EDAP) announced three significant presentations on its high intensity focused ultrasound (HIFU) technology at the 21st Annual International Symposium on Therapeutic Ultrasound (ISTU) from June 7-10, 2022, in Toronto. Topics include the efficacy of TR-HIFU in treating rectal endometriosis, monitoring techniques for HIFU lesions in prostate cancer, and a preclinical evaluation of a dual-mode ultrasound-guided HIFU probe. The findings suggest potential advancements in minimally invasive treatments and enhance EDAP's position in the therapeutic ultrasound market.
EDAP TMS SA reported first quarter 2022 revenue of approximately EUR 13.0 million (USD 14.5 million), reflecting a 26% increase year-over-year. The company sold four Focal One units in Q1 2022, compared to none in Q1 2021. Total revenue from the HIFU business was EUR 3.8 million (USD 4.3 million), significantly up from EUR 1.8 million (USD 2.2 million). However, LITHO business revenue declined to EUR 2.2 million (USD 2.5 million). Gross profit improved to EUR 5.8 million (USD 6.4 million), with a gross margin of 44.3%. As of March 31, 2022, cash reserves were EUR 46.5 million (USD 51.6 million).
EDAP TMS SA (Nasdaq: EDAP) will announce its Q1 2022 financial results on May 17, 2022, after market close. A conference call will take place on May 18, 2022, at 8:30 am EDT, featuring key executives including Marc Oczachowski and Ryan Rhodes. This event will provide insights into the company's performance in the therapeutic ultrasound market, where it leads in minimally invasive medical devices for prostate treatment.
More information and registration details are available through the webcast link.
EDAP TMS SA (Nasdaq: EDAP) will showcase its Focal One® Robotic HIFU platform at the AUA annual meeting from May 13-15 in New Orleans, highlighting its role in prostate cancer treatment. The event will include presentations by leading academic centers on the clinical acceptance of focal therapy. Ryan Rhodes, CEO of EDAP U.S., expressed confidence in Focal One® as advanced technology. Attendees will also experience hands-on training with Focal One® and ExactVu™ Micro-Ultrasound at the EDAP booth, demonstrating its complete solution for prostate cancer diagnostics and treatment.
EDAP TMS SA (Nasdaq: EDAP) announced the placement of three Focal One® machines in prestigious U.S. academic centers during Q1 2022, signaling a strong demand for robotic focal therapy. The placements include New York-Presbyterian/Weill Cornell, Beth Israel Deaconess Lahey Health, and UC Davis Medical Center, the latter marking its fourth installation in the University of California Health System. Additionally, five ExactVu micro-ultrasound systems were sold. The company plans to report full financial results for Q1 2022 in mid-May, highlighting ongoing momentum in prostate cancer treatment technologies.
EDAP TMS SA reported unaudited financial results for 2021, achieving total revenue of EUR 44.1 million (USD 51.9 million), a 5.8% increase from 2020. Notably, US HIFU treatment volumes surged by 65%, reflecting higher adoption rates among urologists. However, the HIFU segment saw a revenue decline to EUR 9.9 million (USD 11.7 million) from EUR 11.4 million (USD 13.1 million) in 2020. Operating loss reached EUR 1.6 million (USD 1.9 million), contrasting with a profit in 2020. The company ended the year with a strong cash position of EUR 47.2 million (USD 53.4 million).
EDAP TMS SA will release its financial results for Q4 2021 on March 30, 2022, after market close. The company will host a conference call on March 31, 2022, at 8:30 am ET, featuring key executives including CEO Marc Oczachowski and CFO François Dietsch. EDAP is a leader in therapeutic ultrasound, offering products such as the Focal One® and ExactVu™ for prostate cancer treatment. The call will provide insights into the company's performance and future outlook, key points for investors to consider.
EDAP TMS SA, a leader in robotic energy-based therapies, reported a remarkable 65% increase in U.S. HIFU treatment volumes for 2021, indicating strong adoption of their Focal One technology despite pandemic challenges. The company expanded its U.S. presence, placing Focal One devices in prestigious hospitals. Additionally, progress was made in R&D, particularly in evaluating HIFU for treating rectal endometriosis and pancreatic cancer. With a solid cash position and successful fourth-quarter momentum, EDAP anticipates a productive 2022, aiming to capitalize on their growth strategy.
FAQ
What is the current stock price of Edap Tms (EDAP)?
What is the market cap of Edap Tms (EDAP)?
